<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002689</url>
  </required_header>
  <id_info>
    <org_study_id>CMM-95079</org_study_id>
    <secondary_id>CDR0000064415</secondary_id>
    <secondary_id>CH/UMC-95079</secondary_id>
    <secondary_id>NCI-V95-0760</secondary_id>
    <nct_id>NCT00002689</nct_id>
  </id_info>
  <brief_title>Radiation Therapy Plus Chemotherapy in Treating Patients With Pancreatic Cancer</brief_title>
  <official_title>Phase II Interstitial Colloidal 32P Integrated in The Treatment of Non-Resectable Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Molecular Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in&#xD;
      chemotherapy use different ways to stop tumor cells from dividing so they stop growing or&#xD;
      die. Radiation therapy combined with chemotherapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of brachytherapy followed by external-beam&#xD;
      radiation therapy plus chemotherapy in treating patients who have pancreatic cancer that&#xD;
      cannot be removed surgically.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response/remission rate, survival, and degree of local control from&#xD;
           interstitial colloidal phosphorus P32 followed by external beam radiotherapy and&#xD;
           chemotherapy in patients with unresectable pancreatic cancer.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to prior therapy (yes vs no).&#xD;
&#xD;
      Patients receive dexamethasone intratumorally, then macroaggregated albumin and interstitial&#xD;
      phosphorus P32 intratumorally. Most patients receive a second course of this brachytherapy.&#xD;
&#xD;
      Patients then proceed to chemoradiotherapy beginning 7-14 days after brachytherapy.&#xD;
      Radiotherapy is administered 5 days a week for 6.4 weeks. Fluorouracil IV is administered&#xD;
      every other day for 4 doses during weeks 1 and 2.&#xD;
&#xD;
      Patients are followed monthly for 1 year then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 48 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 1995</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of remission</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patterns of failure</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>phosphorus P32</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically proven unresectable adenocarcinoma of the pancreas limited to the head,&#xD;
             body, or tail of the pancreas&#xD;
&#xD;
               -  Diameter no greater than 5 cm&#xD;
&#xD;
               -  Volume no greater than 66 mL&#xD;
&#xD;
          -  No ascites (with or without tumor cells)&#xD;
&#xD;
          -  No endoscopically proven tumor penetration of duodenum or stomach&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 70-100%&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL (transfusion allowed)&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  No hepatic disease&#xD;
&#xD;
          -  At least 50% uptake of technetium-sulfur colloid in normal liver if cirrhosis&#xD;
             suspected&#xD;
&#xD;
          -  No vascular occlusion of portal system&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  BUN no greater than 25 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No Crohn's disease, ulcerative colitis, or other inflammatory bowel disease&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  If prior chemotherapy, test dose of colloidal phosphorous P32 administered prior to&#xD;
             attempted treatment&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to pancreas, liver, or upper gastrointestinal tract&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  No complete surgical resection&#xD;
&#xD;
          -  No splenectomy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley E. Order, MD, ScD, FACR</last_name>
    <role>Study Chair</role>
    <affiliation>Center for Molecular Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northside Hospital Cancer Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342-1611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Molecular Medicine</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 17, 2013</last_update_submitted>
  <last_update_submitted_qc>July 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2013</last_update_posted>
  <keyword>stage I pancreatic cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>adenocarcinoma of the pancreas</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

